PPI Deprescribing: Ascension

Tonya Thomas, PharmD

Clinical Pharmacist

Saint Thomas West Hospital Nashville, TN, USA







Learning Objectives

- Describe the necessary support structure for a deprescribing initiative
- Identify strategies for successful implementation of a deprescribing initiative
- Explain the key learning points in the implementation process





Deprescribing Initiative: Process Map

Determine team leaders and stakeholders

Define AIM statement

Create Driver Diagram

Identify Intervention Strategies

Measure **Outcomes**





Ascension PPI Deprescribing: Key System Stakeholders



David Pryor, MD **Executive Vice President**



John Pirolo, MD Senior Vice President Chief Clinical Officer, Ascension Chief Medical Information Officer, Ascension

Local Stakeholders engaged for each site:

- **Physician Champion**
- Pharmacist Champion
- Informatics Champion





Ascension PPI Deprescribing: Team Leaders

| Day-to-Day Leader | Patrick Leinauer, PMP | Program Manager |
|-----------------------|---|--|
| Senior Leader/Sponsor | Ann Hendrich, PhD, RN, FAAN | Senior Vice President of Quality and Safety Executive Director of the Ascension Health Patient Safety Organization (PSO) Chief Nursing Officer |
| Clinical Champion(s) | Karen Smethers, PharmD Kevin Grady, MD | Director, Clinical Services Chief Medical Officer St John Providence Medical Center |
| | Said Soubra, MD | Chief Medical Officer Seton Medical Center, Williamson |
| | Gregory James, MD | Chief Clinical Officer Saint Thomas Health |
| Informatics Team Lead | Dan Leffler, DPh, MS | Senior Director, Pharmacy Information Systems |






Ascension PPI Deprescribing: Team Leaders

On Site Leaders



Leanne Phillips PharmD, BCPS





Tamara Knight PharmD, BCPS

Network Clinical Pharmacy Specialist – Internal Medicine Seton Healthcare Family



DeeDee Hu PharmD, BCPS

Network Clinical Pharmacy Specialist – Critical Care Seton Healthcare Family



Tonya Thomas PharmD

Clinical Pharmacist Saint Thomas West Hospital





Ascension PPI Deprescribing: AIM Statement

"By July 2018, reduce the use of Proton Pump Inhibitors by 50% in adult patients at three Ascension pilot sites."





PPI Deprescribing: Ascension

Proton Pump Inhibitor Therapy De-Prescribing In the inpatient health-system setting

St. Thomas West Nashville, TN

Seton Healthcare Family Austin, TX

St. Vincent's East Birmingham, AL








Three pilot sites that joined the initiative in June 2017





Ascension PPI Deprescribing: Driver Diagram

pilot sites.







Ascension PPI Deprescribing: Implementation Strategies

- Healthcare Professional Education
 - Indications
 - Criteria for Use
 - Adverse Effects
- Removal of PPI from order sets
- Clinical Decision Support
 - Sentri 7 monitoring
 - Order entry Alert
 - PRN order frequency





Ascension PPI Deprescribing: Sentri 7 Alert




- Identification of all PPI orders
 - Intravenous
 - PO





Ascension PPI Deprescribing: Order Alert




 Requires documentation of medical indication for PPI therapy






Ascension PPI Deprescribing Strategy Timeline







Days of Therapy Per 1000 Patient Days - Ascension







Ascension: Implementation Strategies

- Successes
 - Order Entry Alert
 - Sentri 7 Alert
 - Deprescribing as a culture
- Setbacks
 - PRN PPI indication
 - Pilot sites within a health system
 - Conversion of Electronic Medical Records (Upgrade)
 - Prescriptive habits perpetual education
- Key Learning Points
 - Identification of key stakeholders and leadership for support and success
 - Consistent measure and communication of current status to maintain engagement
 - Education as a foundation for change



